nContact Achieves IP Milestone: Solidifying its Pioneering Position in Epicardial-Endocardial Ablation For Cardiac Arrhythmias

MORRISVILLE, N.C.--(BUSINESS WIRE)--nContact, Inc., the leading innovator in epicardial ablation devices, reached a key intellectual property milestone. The United States Patent and Trademark Office recently issued four patents to the company covering essential components of the multidisciplinary epicardial-endocardial approach pioneered by the company and used by physicians to treat cardiac arrhythmias.

“These patents further demonstrate our focus on creating novel procedures and products that enable combining the best practices of endoscopic surgeons and electrophysiologists to provide new arrhythmia treatment options that benefit patients.”

The issued US Patents (US Patents 8,241,273; 8,211,011; 8,235,990; and 8,267,951) specifically cover multidisciplinary approaches in which epicardial and endocardial cardiac ablation synergistically complete linear lesions, as well as devices and methods that enable creating consistent linear lesions under direct visualization without any chest incisions. The patented methodology and devices expand nContact’s intellectual property portfolio and augment its ownership of vacuum integrated epicardial ablation devices.

Co-inventor Sidney Fleischman commented, “These patents further demonstrate our focus on creating novel procedures and products that enable combining the best practices of endoscopic surgeons and electrophysiologists to provide new arrhythmia treatment options that benefit patients.”

About nContact, Inc.

nContact, Inc. is the leading innovator in epicardial ablation devices and techniques. Its mission is to transform the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias.

Its lead technologies, the EPi-Sense® and Numeris® Coagulation System with VisiTrax®, have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

The Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. The EPi-Sense® device is not available in the United States. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, U.S.A.